Michael Elliot Shankman - 15 May 2025 Form 4 Insider Report for Lexaria Bioscience Corp. (LEXX)

Reporting relationship: Chief Financial Officer
Issuer ticker: LEXX
Reported as of: 15 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 May 2025, 16:51:22 UTC
Prior SEC filing: 02 Oct 2024
Source filing: View source filing
Reporting owner signature: /Michael Shankman/

Key filing fact

Michael Elliot Shankman filed Form 4 for Lexaria Bioscience Corp. (LEXX) on 16 May 2025.

Key facts

This page summarizes Michael Elliot Shankman's Form 4 filing for Lexaria Bioscience Corp. (LEXX).
1 reported transaction and 2 derivative rows are listed below.
Accepted by SEC: 16 May 2025, 16:51.

Change

Previous filing in this sequence was filed on 02 Oct 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002035175 Primary reporting owner

Shankman Michael Elliot

Relationship: Chief Financial Officer
Address: 406 NATALIE LANE, DANVILLE
Signature: /Michael Shankman/
Signature date: 16 May 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LEXX transaction Derivative

Stock Options

Award

Transaction value: $0
Shares: +50,000
Change %: +100%
Price: $0.000000
Shares after: 100,000
Date: 15 May 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 50,000
Exercise price: $1.04

LEXX holding Derivative

Stock Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 50,000
Date: 15 May 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 50,000
Exercise price: $3.17
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

20,000 options are exercisable as of February 28, 2025, an additional 15,000 options are exercisable on August 31, 2025 and the remaining 15,000 options are exercisable on August 31, 2026